MX2023009081A - Metodos para detectar aav. - Google Patents

Metodos para detectar aav.

Info

Publication number
MX2023009081A
MX2023009081A MX2023009081A MX2023009081A MX2023009081A MX 2023009081 A MX2023009081 A MX 2023009081A MX 2023009081 A MX2023009081 A MX 2023009081A MX 2023009081 A MX2023009081 A MX 2023009081A MX 2023009081 A MX2023009081 A MX 2023009081A
Authority
MX
Mexico
Prior art keywords
methods
aav
particles
heterogeneity
determining
Prior art date
Application number
MX2023009081A
Other languages
English (en)
Inventor
Xiaoying Jin
Lin Liu
Kate Zhang
Catherine R O''riordan
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59762045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2023009081(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2023009081A publication Critical patent/MX2023009081A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/075—Adenoviridae

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Photoreceptors In Electrophotography (AREA)

Abstract

En la presente divulgación se proporcionan métodos para determinar el serotipo de una partícula de virus y/o para determinar la heterogeneidad de una partícula de virus (p. ej., una partícula de AAV). En otras modalidades, la invención proporciona métodos para determinar la heterogeneidad de partículas de AAV. En algunos aspectos, la invención proporciona partículas virales (p. ej., partículas de rAAV) con estabilidad mejorada y/o eficiencia de la transducción mejorada mediante el incremento de la acetilación y/o desamidación de las proteínas de la cápside.
MX2023009081A 2016-08-15 2019-02-15 Metodos para detectar aav. MX2023009081A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662375314P 2016-08-15 2016-08-15

Publications (1)

Publication Number Publication Date
MX2023009081A true MX2023009081A (es) 2023-08-08

Family

ID=59762045

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019001938A MX2019001938A (es) 2016-08-15 2017-08-14 Metodos para detectar aav.
MX2023009081A MX2023009081A (es) 2016-08-15 2019-02-15 Metodos para detectar aav.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019001938A MX2019001938A (es) 2016-08-15 2017-08-14 Metodos para detectar aav.

Country Status (23)

Country Link
US (2) US11698377B2 (es)
EP (2) EP3851449A1 (es)
JP (3) JP7021191B2 (es)
KR (3) KR102425289B1 (es)
CN (1) CN110168080B (es)
AU (2) AU2017312951B2 (es)
BR (1) BR112019002934A2 (es)
CA (1) CA3033856A1 (es)
CL (2) CL2019000392A1 (es)
CR (1) CR20190127A (es)
CY (1) CY1124364T1 (es)
DK (1) DK3497207T3 (es)
ES (1) ES2863674T3 (es)
HU (1) HUE053747T2 (es)
IL (2) IL264819B1 (es)
MA (1) MA55748A (es)
MX (2) MX2019001938A (es)
PH (1) PH12019500316A1 (es)
SG (2) SG11201901221YA (es)
TN (1) TN2019000047A1 (es)
TW (2) TW202309068A (es)
WO (1) WO2018035059A1 (es)
ZA (1) ZA201900945B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
HRP20240257T1 (hr) 2017-02-28 2024-05-24 The Trustees Of The University Of Pennsylvania Adeno-povezani virusni (aav) clade f vektor i njegova uporaba
CA3091806A1 (en) * 2018-02-27 2019-09-06 The Trustees Of The University Of Pennsylvania Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
BR112020017278A2 (pt) * 2018-02-27 2020-12-22 The Trustees Of The University Of Pennsylvania Vetores de vírus adenoassociado (aav), vetores de aav tendo desamidação de capsídeos reduzida e usos para os mesmos
US20210010028A1 (en) * 2018-03-06 2021-01-14 Voyager Therapeutics, Inc. Insect cell manufactured partial self-complementary aav genomes
EP3829733A1 (en) * 2018-07-27 2021-06-09 Waters Technologies Corporation Liquid chromatography/mass spectrometry methods for the analysis of polar molecules
JP7451497B2 (ja) * 2018-08-21 2024-03-18 マサチューセッツ アイ アンド イヤー インファーマリー アデノ随伴ウイルスの形質導入効率を調節するための組成物および方法
MX2021004533A (es) * 2018-10-25 2021-08-24 Regeneron Pharma Metodos para el analisis de la composicion de la proteina de la capside viral.
MX2022008003A (es) 2020-01-03 2022-10-07 Sarepta Therapeutics Inc Métodos para analizar proteínas de la cápside de aav.
CN115989234A (zh) 2020-01-29 2023-04-18 建新公司 用于眼部基因疗法的经修饰的腺相关病毒衣壳蛋白及其使用方法
CN111517359B (zh) * 2020-04-23 2021-08-20 江南大学 一种手性硫化铜超粒子的合成方法
RU2748540C1 (ru) * 2021-02-08 2021-05-26 Автономная некоммерческая образовательная организация высшего образования "Сколковский институт науки и технологий" Способ детектирования вируса SARS-CoV-2 методом масс-спектрометрии
EP4295158A1 (en) * 2021-02-19 2023-12-27 Waters Technologies Corporation Methods for peptide mapping of adeno-associated virus (aav) proteins
JPWO2022224965A1 (es) * 2021-04-20 2022-10-27
KR20240032120A (ko) * 2021-07-12 2024-03-08 리제너론 파아마슈티컬스, 인크. 바이러스 입자를 검정하기 위한 온라인 고유 질량 분광분석 방법
AU2022309726A1 (en) * 2021-07-12 2024-01-25 Regeneron Pharmaceuticals, Inc. Liquid chromatography assay for determining aav capsid ratio
CN113552349B (zh) * 2021-07-30 2022-07-19 上海勉亦生物科技有限公司 Aav蛋白外壳的检测方法
WO2023132338A1 (ja) * 2022-01-06 2023-07-13 富士フイルム株式会社 タンパク質における糖が結合したアミノ酸部位を同定する方法、及びキット

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204059B1 (en) * 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
WO1998010088A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
JP4827353B2 (ja) 1999-08-09 2011-11-30 ターゲティッド ジェネティクス コーポレイション 鎖内塩基対を形成するような配列の設計による、組換えウイルスベクターからの一本鎖の異種ヌクレオチド配列の発現の増大
DE60117550T2 (de) 2000-06-01 2006-12-07 University Of North Carolina At Chapel Hill Doppelsträngige parvovirus-vektoren
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
SG157224A1 (en) 2001-11-13 2009-12-29 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
EP1496944B1 (en) 2002-05-01 2008-08-20 University of Florida Research Foundation, Inc. Improved raav expression systems for genetic modification of specific capsid proteins
JP2006510875A (ja) * 2002-11-22 2006-03-30 カプリオン ファーマシューティカルズ インコーポレーティッド コンステレーションマッピングおよびそれらの使用
US7510872B2 (en) 2003-02-26 2009-03-31 Nationwide Children's Hospital Recombinant adeno-associated virus production
EP2281877A3 (en) 2003-05-21 2011-06-01 Genzyme Corporation Methods for producing preparations of recombinant AAV virions substantially free of empty capsids
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
US9441244B2 (en) * 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
WO2006119432A2 (en) 2005-04-29 2006-11-09 The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes
AU2006304997B2 (en) * 2005-10-20 2012-03-01 Uniqure Ip B.V. Improved AAV vectors produced in insect cells
EP2007795B1 (en) 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid proteins
WO2010031865A1 (en) 2008-09-19 2010-03-25 Charitē Universitätsmedizin Berlin Identification and characterisation of recombinant viral gene therapy vectors
EP2396343B1 (en) * 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
SI3067417T1 (sl) 2009-06-16 2018-11-30 Genzyme Corporation Izboljšani postopki čiščenja vektorjev rekombinantnega AAV
DK2561073T3 (en) 2010-04-23 2016-12-12 Univ Massachusetts Aav vectors targeted to central nervous system and methods of use thereof
WO2012031245A1 (en) * 2010-09-03 2012-03-08 North Carolina Central University Biodegradable liquogel and ph sensitive nanocarriers
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
SG10201601110VA (en) 2011-02-17 2016-03-30 Univ Pennsylvania Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer
EP2748185A1 (en) 2011-08-24 2014-07-02 The Board of Trustees of The Leland Stanford Junior University New aav capsid proteins for nucleic acid transfer
MY172457A (en) 2012-04-18 2019-11-26 Childrens Hospital Philadelphia Composition and methods for highly efficient gene transfer using aav capsid variants
US20140017716A1 (en) * 2012-07-11 2014-01-16 Siscapa Assay Technologies, Inc. Proteolytic digestion kit with dried reagents
GB201401707D0 (en) 2014-01-31 2014-03-19 Sec Dep For Health The Adeno-associated viral vectors
CA2942289C (en) * 2014-03-10 2024-05-21 Uniqure Ip B.V. Further improved aav vectors produced in insect cells

Also Published As

Publication number Publication date
CR20190127A (es) 2019-06-25
EP3497207A1 (en) 2019-06-19
HUE053747T2 (hu) 2021-07-28
CL2019002912A1 (es) 2020-03-06
TW202309068A (zh) 2023-03-01
TW201825898A (zh) 2018-07-16
CN110168080B (zh) 2024-05-31
MX2019001938A (es) 2019-07-04
BR112019002934A2 (pt) 2019-05-14
SG11201901221YA (en) 2019-03-28
SG10201913002QA (en) 2020-03-30
TWI781953B (zh) 2022-11-01
CA3033856A1 (en) 2018-02-22
CN110168080A (zh) 2019-08-23
KR20230078834A (ko) 2023-06-02
WO2018035059A1 (en) 2018-02-22
RU2019107207A (ru) 2020-09-15
MA55748A (fr) 2022-03-02
DK3497207T3 (da) 2021-03-22
IL264819B1 (en) 2024-06-01
US20240044910A1 (en) 2024-02-08
WO2018035059A9 (en) 2019-03-14
RU2019107207A3 (es) 2021-04-29
CL2019000392A1 (es) 2019-05-10
KR102538037B1 (ko) 2023-05-30
EP3851449A1 (en) 2021-07-21
JP2019533803A (ja) 2019-11-21
AU2017312951A1 (en) 2019-04-04
AU2024200349A1 (en) 2024-02-08
KR102425289B1 (ko) 2022-07-27
EP3497207B1 (en) 2021-01-06
CY1124364T1 (el) 2022-07-22
PH12019500316A1 (en) 2019-08-05
ES2863674T3 (es) 2021-10-11
JP2024023460A (ja) 2024-02-21
TN2019000047A1 (en) 2020-07-15
JP7021191B2 (ja) 2022-02-16
IL264819A (es) 2019-04-30
KR20190039253A (ko) 2019-04-10
AU2017312951B2 (en) 2024-02-08
US11698377B2 (en) 2023-07-11
US20210041451A1 (en) 2021-02-11
IL312792A (en) 2024-07-01
ZA201900945B (en) 2021-06-30
JP2022064980A (ja) 2022-04-26
KR20220107327A (ko) 2022-08-02

Similar Documents

Publication Publication Date Title
MX2023009081A (es) Metodos para detectar aav.
WO2017066764A3 (en) Modification of n-terminal region of capsid proteins for enhanced properties of adeno-associated viruses
TR201901582T4 (tr) Kapsid
MX2017012097A (es) Variantes de virus adenoasociado y métodos de uso de estas.
EA201791630A1 (ru) Аналитическое ультрацентрифугирование для определения характеристик рекомбинантных вирусных частиц
EA201792236A1 (ru) Получение увеличенных в размере векторов на основе аденоассоциированного вируса
BR112018011881A2 (pt) proteínas capsidiais modificadas para liberação aumentada de vetores de parvovírus
PE20150163A1 (es) Composicion y metodos para una transferencia de genes altamente eficiente usando variantes capside aav
SG10201803081TA (en) Oncolytic adenovirus encoding a b7 protein
MX2019006467A (es) Composiciones y métodos para mejorar la expresión génica.
MX2022003681A (es) Caracterizacion de particulas virales de terapia genetica a traves del uso de cromatografia de exclusion de tama?os y las tecnologias de dispersion de la luz en multiples angulos.
MX2019010910A (es) Viriones de virus adenoasociados con capsides variantes y metodos para su uso.
MX2016010649A (es) Vector de virus adeno-asociado.
WO2009108274A3 (en) Methods and compositions for adeno-associated virus (aav) with hi loop mutations
MX352604B (es) Composiciones inmunogenicas de la glucoproteina g de los virus hendra y nipah.
MX2016013584A (es) Parvovirus porcino.
MX2020005282A (es) Vector para la produccion de particulas aav.
WO2012064960A3 (en) Compositions and methods for generating adeno-associated viral vectors with undetectable capsid gene contamination
MX2014007516A (es) Procesos que utilizan vlps con capsides resistentes a hidrolasas.
NZ741875A (en) Canine parvovirus (cpv) virus-like particle (vlp) vaccines and uses thereof
GB201915905D0 (en) Viruses with modified capsid proteins
MY179251A (en) Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
EA201691120A1 (ru) Векторные композиции и способы индукции усиленного иммунного ответа с использованием векторов поксвируса
SG11201810015YA (en) Particle for the encapsidation of a genome engineering system
SG11201810014UA (en) Viral particle for rna transfer, especially into cells involved in immune response